Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06377124 | A Smart Self-Management Support Programme (3S) to Improve Quality of Life in Lung Cancer Patients | recruiting | N/A | 320 | The University of Hong KongOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06717243 | Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)(STRATUS) | recruiting | — | 111 | Oncology Center of Biochemical Education And ResearchOTHER | 2 |
| Mar 19, 2025 |
| clinicaltrials |
| NCT06883136 | Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients | enrolling by invitation | — | 43 | Qianfoshan HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883552 | An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 21 | Sichuan UniversityOTHER | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04263467 | High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM)(HIAIM) | active not recruiting | N/A | 54 | Herlev HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06876675 | LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer | enrolling by invitation | — | 167 | Peking University Third HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06663098 | Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).(CARRY-ON) | recruiting | Phase 2 | 142 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05844150 | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | active not recruiting | Phase 2 | 50 | Biotheus Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06617416 | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06730295 | Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06756295 | A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)(FAST-CR) | not yet recruiting | Early Phase 1 | 154 | Fengming KongOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06869239 | Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy | recruiting | — | 65 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03987633 | EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality(EMPOWER) | recruiting | — | 200,000 | Future Genetics LimitedOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05463913 | Lung Nodule Detection Using Ultra-long FOV PET/CT | recruiting | Phase 4 | 20 | University Medical Center GroningenOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863506 | Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC | recruiting | Phase 2 | 78 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863818 | Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs | active not recruiting | — | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06643000 | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis | recruiting | N/A | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04777084 | The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. | recruiting | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06069570 | Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases | recruiting | Phase 1 | 48 | Kiromic BioPharma Inc.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06856798 | Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective | not yet recruiting | — | 120 | Ziming LiOTHER | 0 | Mar 4, 2025 | clinicaltrials |
| NCT06853678 | Second-line Immunotherapy for ES-SCLC | recruiting | N/A | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06854939 | A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.(MRDSEEKER) | not yet recruiting | — | 350 | National Cancer Center, JapanOTHER_GOV | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | recruiting | Phase 1 | 80 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06849518 | Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer | recruiting | N/A | 30 | Ballad HealthOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06851169 | This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response | not yet recruiting | Phase 2 | 58 | Tang-Du HospitalOTHER | 0 | Feb 28, 2025 | clinicaltrials |
| NCT03514329 | Vapor Ablation for Localized Cancer Lesions(VAPORIZED) | not yet recruiting | N/A | 10 | Uptake Medical Technology, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT06692972 | The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy | recruiting | — | 500 | China-Japan Friendship HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06748495 | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | active not recruiting | — | 600 | Hunan Cancer HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06848426 | Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial | not yet recruiting | N/A | 100 | Jiangxi Provincial People's HopitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06848738 | Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound(IMPROVED) | enrolling by invitation | N/A | 362 | Zealand University HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06849167 | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC | recruiting | Phase 2 | 63 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06846736 | ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study(ALKDigPath) | enrolling by invitation | — | 200 | Sheba Medical CenterOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06846762 | DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC | recruiting | — | 508 | Baohui HanOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06847334 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 772 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 26, 2025 | clinicaltrials |
| NCT05477979 | The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG) | recruiting | — | 750 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06843707 | Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics. | recruiting | — | 2,500 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06484816 | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05281406 | Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | recruiting | Phase 2 | 50 | Goethe UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06771960 | Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC | recruiting | — | 120 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06837948 | Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06828757 | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 94 | Hunan Province Tumor HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06833632 | Detection of Circulating Tumour Cells, Spread Through Air Space in Patients With Lung Cancer | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06835231 | Broncho-Vascular Lung Sparing Reconstructions and Pneumonectomies in Patients With Non Small Cell Lung Cancer | active not recruiting | — | 140 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients(CRISP) | recruiting | — | 12,400 | AIO-Studien-gGmbHOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06272864 | BostonGene and Exigent Genomic INsight Study(BEGIN) | recruiting | — | 400 | BostonGeneINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06458894 | Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients. | recruiting | N/A | 100 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Feb 17, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Mar 19, 2025source: clinicaltrials